Summit Therapeutics released an update on its ivonescimab trial, reporting a sustained survival benefit in patients.
Summit Therapeutics has updated data from its ivonescimab clinical trial, reporting a sustained survival benefit. The company shared the findings as part of an ongoing update on the program's developmental progress.
Further verified details on the trial results were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
